Drug Trial Radar · NCT06840886
A Study of PHST001 in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
426
Planned (sponsor's estimate)
Start
Mar 31, 2025
Primary completion
Apr 2029
Study completion Apr 2031
Sponsor
- Lead sponsor
- Pheast TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies. The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.
Conditions
- Advanced Solid Tumors
- Ovarian Cancer
- Endometrial Cancer
- Cholangiocarcinoma
- CNS Tumor
- Breast Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
- Carcinosarcoma, Ovarian
Interventions
PHST001Biological
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.
PaclitaxelDrug
Paclitaxel used as per standard of care.
TopotecanDrug
Topotecan used as per standard of care.
DoxorubicinDrug
Doxorubicin used as per standard of care.
FOLFIRIDrug
FOLFIRI used as per standard of care.
FOLFOXDrug
FOLFOX used as per standard of care.
GemcitabineDrug
Gemcitabine used as per standard of care.
Mirvetuximab SoravtansineBiological
Mirvetuximab soravtansine used as per standard of care.
Trastuzumab DeruxtecanBiological
Trastuzumab deruxtecan used as per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose of PHST001 through 21 days after the first dose of PHST001
- Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From signed consent up to 90 days after the last dose of PHST001
- Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
- Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
- Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
- Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
- Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)Time frame: From screening and during treatment up to 2 years
- Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)Time frame: From screening and during treatment up to 2 years
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Precision NextGen Oncology & Research Center
Beverly Hills, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Stanford University School of Medicine
Palo Alto, California · Recruiting
Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
Denver, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
START Center for Cancer Research - Midwest
Grand Rapids, Michigan · Recruiting
START Center for Cancer Research - Long Island New York
Lake Success, New York · Recruiting
Mount Sinai
New York, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Sarah Cannon Research Institute (SCRI) Oncology Partners
Nashville, Tennessee · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
START Center for Cancer Research - Texas
Fort Worth, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology - Dallas
Irving, Texas · Recruiting
START Center for Cancer Research - San Antonio
San Antonio, Texas · Recruiting
University of Texas (UT) Health
San Antonio, Texas · Recruiting
NEXT Oncology - Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.